
Opinion|Videos|August 7, 2024
Efficacy and Safety of Subcutaneous Infliximab
Author(s)Jean-Frederic Colombel, MD
A key opinion leader analyzes the clinical remission and endoscopic response data from the LIBERTY CD and LIBERTY UC trials for subcutaneous infliximab-dyyb injection, contrasts it with intravenous infliximab, and evaluates the drug's safety and efficacy profile.
Advertisement
- What are the key findings regarding the clinical remission and endoscopic response of subcutaneous infliximab-dyyb injection from the LIBERTY CD and LIBERTY UC trials?
- How does subcutaneous infliximab injection compare to IV infliximab in terms of sustenance of drug levels?
- Are there any clinical advantages of the subcutaneous delivery over the IV route?
- How does the safety profile of subcutaneous infliximab injection compare to IV infliximab?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia
2
Delgocitinib Approval Fills a Long-Standing Gap in Chronic Hand Eczema Treatment
3
Q&A: Cardiometabolic Care Cascade Failure Points, with Rishi Wadhera, MD, MPP, MPhil
4
Q&A: CKM Care, IRA Policy, and Specialty Silos, With Rishi Wadhera, MD, MPP, MPhil
5
























































































